Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of BGF MDI with Different Propellants
NCT04600505Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Observed Concentration at 24 hours, Area Under the Concentration-time Curve Extrapolated to Infinity at 24 hours and 1 more. Started Oct 2020; status: completed.
02
Drugs
Breztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04600505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04600505.